Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer.

BMC Immunol · 2019 · PMC6894239 · PMID 31801459

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Fc-μTP-L309C exhibited a dose-response as even doses of 50 mg/kg and 100 mg/kg showed a trend for efficacy with 200 mg/kg being the most efficacious.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.